AU2002351898A1 - Method for obtaining the elimination of integrated and functional viruses from infected mammal cells - Google Patents

Method for obtaining the elimination of integrated and functional viruses from infected mammal cells

Info

Publication number
AU2002351898A1
AU2002351898A1 AU2002351898A AU2002351898A AU2002351898A1 AU 2002351898 A1 AU2002351898 A1 AU 2002351898A1 AU 2002351898 A AU2002351898 A AU 2002351898A AU 2002351898 A AU2002351898 A AU 2002351898A AU 2002351898 A1 AU2002351898 A1 AU 2002351898A1
Authority
AU
Australia
Prior art keywords
elimination
obtaining
integrated
mammal cells
infected mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002351898A
Inventor
Emmanuelle Adam
Arsene Burny
Vincent Quivy
Carine Van Lint
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Original Assignee
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB filed Critical Universite Libre de Bruxelles ULB
Publication of AU2002351898A1 publication Critical patent/AU2002351898A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002351898A 2001-12-21 2002-12-23 Method for obtaining the elimination of integrated and functional viruses from infected mammal cells Abandoned AU2002351898A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01870289 2001-12-21
EP01870289.4 2001-12-21
PCT/BE2002/000197 WO2003053468A1 (en) 2001-12-21 2002-12-23 Method for obtaining the elimination of integrated and functional viruses from infected mammal cells

Publications (1)

Publication Number Publication Date
AU2002351898A1 true AU2002351898A1 (en) 2003-07-09

Family

ID=8185077

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002351898A Abandoned AU2002351898A1 (en) 2001-12-21 2002-12-23 Method for obtaining the elimination of integrated and functional viruses from infected mammal cells

Country Status (2)

Country Link
AU (1) AU2002351898A1 (en)
WO (1) WO2003053468A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627048A4 (en) * 2003-05-16 2008-10-15 Univ Maryland Biotech Inst Compositions for down-regulation of ccr5 expression and methods of use therefor
BRPI0613429A2 (en) 2005-07-14 2009-02-10 Takeda San Diego Inc histone deacetylase inhibitors
CA2650520A1 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
WO2008083288A2 (en) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals Purifiction of romidepsin
WO2010049182A2 (en) * 2008-10-29 2010-05-06 Istituto Superiore Di Sanitá Treatment of retroviral reservoirs exploiting oxidative stress
JP6049614B2 (en) 2010-07-12 2016-12-21 セルジーン コーポレイション Romidepsin solid forms and their use
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof

Also Published As

Publication number Publication date
WO2003053468A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
EP1241577A3 (en) Methods and arrangements for improved parity-stripe processing
AU2002248383A1 (en) So$g(x) tolerant no$g(x) trap catalysts and methods of making and using the same
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
WO2003022987A9 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2002351898A1 (en) Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
AU2003229474A1 (en) Methods and compositions for detecting sars virus
AU2003268145A1 (en) Methods for propagating adenovirus and virus produced thereby
GB0130947D0 (en) Improved sample preparation for the detection of infectious agents
AU2002311477A1 (en) Method for detection of foot-and-mouth disease virus
AU2002359792A1 (en) Methods and compositions for the inhibition of viral release
AUPR963401A0 (en) Methods for the enhancement of complex peaks
AU2003287216A1 (en) Gb virus c and methods of treating viral infections
AU2002323443A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
AU2002329176A1 (en) Targeted particles and methods of using the same
AU2002333476A1 (en) Means and methods for determining the presence of active herpes virus
WO2003020115A9 (en) Methods and compositions for the detection of cancer
AU2003299493A1 (en) Compositions and methods for the treatment of hepatitis c virus infection
AU2001234644A1 (en) Methods for inactivating viruses
AU2002255937A1 (en) Methods for the treatment of hiv and other viruses
AU2002326797A1 (en) Methods and compositions for the detection of cancer
AU2002327832A1 (en) Process for the detection of oxidative stress and kit for its implementation
AU2002321928A1 (en) Probe for detection of enteric virus detection kit and method for enteric virus with the same
GB0101365D0 (en) Methods and means for reducing the incidence of diseases and identifying diseases
NO20005976A (en) Device for mounting / dismounting belts, as well as use and procedure for the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase